1
|
Chistiakov DA, Tyurina I. Current strategies and perspectives in insulin gene therapy for diabetes. Expert Rev Endocrinol Metab 2007; 2:27-34. [PMID: 30743746 DOI: 10.1586/17446651.2.1.27] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Insulin gene therapy is an approach that might overcome the weakness of islet cell therapy owing to its vulnerability to autoimmune attack. There are several mandatory conditions for successful insulin gene therapy. Efficient insulin gene therapy should have an effective insulin gene delivery mechanism, a system of regulation of the insulin biosynthesis that responds to glucose within extremely narrow physiological limits, a system of insulin processing into its active form and a choice of appropriate target cells, which possess biochemical characteristics similar to β cells, but are not targets for β-cell-specific self-reactivity. In this article, advantages and disadvantages of non-β-cell types that are most likely to be used for generating surrogate insulin-producing β cells are compared. Current achievements in insulin gene therapy are critically evaluated and future challenges are discussed.
Collapse
Affiliation(s)
- Dimitry A Chistiakov
- a Assistant Professor, University of Pittsburgh Medical Center, Department of Pathology, 3550 Terrace Street, Pittsburgh, PA, 15261, USA.
| | - Inna Tyurina
- b Executive Manager and Consultant, Public Relations and Consulting Group 'Imya', 8th Tekstilschikov Street 11, 109129, Moscow, Russia.
| |
Collapse
|
2
|
Verhaagh S, de Jong E, Goudsmit J, Lecollinet S, Gillissen G, de Vries M, van Leuven K, Que I, Ouwehand K, Mintardjo R, Weverling GJ, Radošević K, Richardson J, Eloit M, Lowik C, Quax P, Havenga M. Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors. J Gen Virol 2006; 87:255-265. [PMID: 16432010 DOI: 10.1099/vir.0.81293-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Wild-type strains of mice do not express CD46, a high-affinity receptor for human group B adenoviruses including type 35. Therefore, studies performed to date in mice using replication-incompetent Ad35 (rAd35) vaccine carriers may underestimate potency or result in altered vector distribution. Here, it is reported that CD46 transgenic mice (MYII-strain) express CD46 in all major organs and that it functions as a receptor for rAd35 vectors. Similar to monkeys and humans, MYII mice highly express CD46 in their lungs and kidneys and demonstrate low expression in muscle. Upon intravenous administration, rAd35 vector genomes as well as expression are detected in lungs of MYII mice, in contrast to wild-type littermates. Expression was predominantly detected in lung epithelial cells. Upon intramuscular administration, the initial level of luciferase expression is higher in MYII mice as compared with wild-type littermates, in spite of the fact that CD46 expression is low in muscle of MYII mice. The higher level of expression in muscle of MYII mice results in prolonged gene expression as assessed by CCD camera imaging for luciferase activity. Finally, a significant dose-sparing effect in MYII mice as compared with wild-type littermates on anti-SIVgag CD8+ T-cell induction following intramuscular vaccination with an rA35.SIVgag vaccine was observed. This dose-sparing effect was also observed when reinfusing dendritic cells derived from MYII mice after exposure to rAd35.SIVgag vaccine as compared with rAd35.SIVgag exposed dendritic cells from wild-type littermates. It was concluded that MYII mice represent an interesting preclinical model to evaluate potency and safety of rAd35 vectors.
Collapse
Affiliation(s)
- Sandra Verhaagh
- Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
| | - Esmeralda de Jong
- Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
| | - Jaap Goudsmit
- Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
| | | | - Gert Gillissen
- Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
| | | | | | - Ivo Que
- Department of Endocrinology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Krista Ouwehand
- Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
| | - Ratna Mintardjo
- Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
| | | | | | | | - Marc Eloit
- Ecole National Veterinaire d'Alfort, Alfort, France
| | - Clemens Lowik
- Department of Endocrinology, Leiden University Medical Centre, Leiden, The Netherlands
| | - Paul Quax
- Gaubius Laboratory, TNO Leiden, The Netherlands
| | - Menzo Havenga
- Crucell Holland BV, Archimedesweg 4, 2333 CN Leiden, The Netherlands
| |
Collapse
|
3
|
Flint PW, Li ZB, Lehar M, Saito K, Pai SI. Laryngeal muscle surface receptors identified using random phage library. Laryngoscope 2006; 115:1930-7. [PMID: 16319601 DOI: 10.1097/01.mlg.0000172273.98418.8d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVES The ultimate goal of this study is to improve the efficiency of gene transfer in mammalian muscle by developing targeted adenoviral vectors. Altering the tropism of viral vectors to recognize tissue specific antigens is one method to achieve this goal. This approach requires identification of cell-surface receptors and the insertion of target peptide sequences into the adenoviral fiber protein. In this study, phage biopanning was performed on cultured rat skeletal and laryngeal muscle to identify cell-surface receptors. STUDY DESIGN In vitro cell culture and in vivo animal model. METHODS M-13 Phage biopanning was used for muscle cell-surface receptor analysis on cultured rat skeletal and laryngeal muscle. Nonbinding and binding phage to cultured skeletal and laryngeal muscle were screened for muscle specific surface peptides. In vivo studies were then performed using muscle specific phage. RESULTS Skeletal muscle specific binding by the YASTNPM phage was observed by in vivo immunostaining. Phage titering demonstrated a 10(9)-fold increase in skeletal muscle binding compared with nontarget tissue. A peptide sequence (NPSQVKH) specific for laryngeal muscle yielded a 10(7)-fold increase in laryngeal muscle phage titer compared with nontarget tissue. CONCLUSIONS These results identify muscle cell-surface receptors that may be used as potential targets for genetic modification of adenovirus tropism. Moreover, phage specificity for skeletal and laryngeal muscle indicates specific muscle groups may be targeted.
Collapse
Affiliation(s)
- Paul W Flint
- Department of Otolaryngology-Head and Neck Surgery Johns Hopkins University, Baltimore, Maryland, USA.
| | | | | | | | | |
Collapse
|
4
|
Matyas L, Schulte KL, Dormandy JA, Norgren L, Sowade O, Grötzbach G, Palmer-Kazen U, Rubanyi GM, Wahlberg E. Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4. Hum Gene Ther 2006; 16:1202-11. [PMID: 16218781 DOI: 10.1089/hum.2005.16.1202] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The objectives of this study were to assess the safety and potential clinical efficacy of adenovirus-delivered fibroblast growth factor-4 (Ad5FGF-4) by intramuscular injection into patients with critical limb ischemia (CLI). This study was a double-blind, randomized, placebo-controlled study with escalating dose groups of 2.87 x 10(8) to 2.87 x 10(10) viral particles. Thirteen patients with CLI were randomized to receive active drug (n = 10) or placebo (n = 3). Safety evaluations and efficacy parameters (ankle-brachial index, digital subtraction angiograms, magnetic resonance imaging, and scintigraphy) were performed at baseline and for 12 weeks after treatment. Injections of Ad5FGF-4 were generally well tolerated and considered safe. Transfection efficacy at these concentrations may have been limited or local. The small sample size did not allow any firm conclusions regarding clinical efficacy but a trend toward more and slightly larger blood vessels was observed in the angiograms. It is concluded that intramuscular injection of Ad5FGF-4 into CLI patients seemed safe, but transfection efficacy was limited at the assessed doses. Conclusions regarding clinical efficacy are impossible to draw from this small patient cohort.
Collapse
Affiliation(s)
- L Matyas
- Borsod County Hospital, H-3501 Miskolc, Hungary
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Hou ST, Dove M, Anderson E, Zhang J, MacKenzie CR. Identification of polypeptides with selective affinity to intact mouse cerebellar granule neurons from a random peptide-presenting phage library. J Neurosci Methods 2004; 138:39-44. [PMID: 15325109 DOI: 10.1016/j.jneumeth.2004.03.013] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2003] [Revised: 02/20/2004] [Accepted: 03/04/2004] [Indexed: 11/29/2022]
Abstract
Targeting of postmitotic neurons selectively for gene delivery poses a challenge. One way to achieve such a selective targeting is to link the gene delivery vector with small ligand-binding polypeptides which have selective affinity to intact neurons. In order to identify such novel neuron selective polypeptides, we screened a phage-display library displaying random 12-mer polypeptides and subtractively bio-panned for clones having selectivity towards cultured mouse cerebellar granule neurons. The selected phage clones were amplified and sequenced. Affinities of these clones to neurons were determined by the visible presence or absence of fluorescence of phage particles as detected by immunocytochemistry using an antibody to M-13 phage. This affinity was further qualified by how much phage was bound, and where in or on the cell it tended to accumulate. The selectivity of binding to neurons was determined by the negative binding of these clones to several cultured non-neuronal cells, including, primary glial cells, NT2 cells, human embryonic kidney 293 cells, neuroblastoma cells, and mouse 3T3 cells. Among the 46 clones that we have sequenced and characterized, four clones appeared to have excellent selectivity in binding to neurons. Homology comparison of these polypeptides revealed that three of them contained a consensus D(E)-W(F)-I(N)-D-W motif. This motif was also present in the Bdm1 gene product which was predominantly expressed in postnatal brains. Further characterizations of these polypeptides are required to reveal the utilities of these peptides to function as an effective linker to facilitate gene transfer selectively to neurons.
Collapse
Affiliation(s)
- Sheng T Hou
- Experimental Stroke Group, NRC Institute for Biological Sciences, National Research Council Canada, 1500 Montreal Road Labs, Bldg. M-54, Ottawa, Ont., Canada K1A 0R6.
| | | | | | | | | |
Collapse
|
7
|
Rajagopalan S, Mohler ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial Disease. Circulation 2003; 108:1933-8. [PMID: 14504183 DOI: 10.1161/01.cir.0000093398.16124.29] [Citation(s) in RCA: 397] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Background—
“Therapeutic angiogenesis” seeks to improve perfusion by the growth of new blood vessels. The Regional Angiogenesis with Vascular Endothelial growth factor (RAVE) trial is the first major randomized study of adenoviral vascular endothelial growth factor (VEGF) gene transfer for the treatment of peripheral artery disease (PAD).
Methods and Results—
This phase 2, double-blind, placebo-controlled study was designed to test the efficacy and safety of intramuscular delivery of AdVEGF121, a replication-deficient adenovirus encoding the 121-amino-acid isoform of vascular endothelial growth factor, to the lower extremities of subjects with unilateral PAD. In all, 105 subjects with unilateral exercise-limiting intermittent claudication during 2 qualifying treadmill tests, with peak walking time (PWT) between 1 to 10 minutes, were stratified on the basis of diabetic status and randomized to low-dose (4×10
9
PU) AdVEGF121, high-dose (4×10
10
PU) AdVEGF121, or placebo, administered as 20 intramuscular injections to the index leg in a single session. The primary efficacy end point, change in PWT (ΔPWT) at 12 weeks, did not differ between the placebo (1.8±3.2 minutes), low-dose (1.6±1.9 minutes), and high-dose (1.5±3.1 minutes) groups. Secondary measures, including ΔPWT, ankle-brachial index, claudication onset time, and quality-of-life measures (SF-36 and Walking Impairment Questionnaire), were also similar among groups at 12 and 26 weeks. AdVEGF121 administration was associated with increased peripheral edema.
Conclusions—
A single unilateral intramuscular administration of AdVEGF121 was not associated with improved exercise performance or quality of life in this study. This study does not support local delivery of single-dose VEGF
121
as a treatment strategy in patients with unilateral PAD.
Collapse
Affiliation(s)
- Sanjay Rajagopalan
- Department of Internal Medicine, Section of Vascular Medicine, Division of Cardiovascular Medicine, University of Michigan Health System, Ann Arbor, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Volpers C, Thirion C, Biermann V, Hussmann S, Kewes H, Dunant P, von der Mark H, Herrmann A, Kochanek S, Lochmüller H. Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol 2003; 77:2093-104. [PMID: 12525644 PMCID: PMC140881 DOI: 10.1128/jvi.77.3.2093-2104.2003] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Adenovirus vectors have been targeted to different cell types by genetic modification of the capsid or by using recombinant or chemically engineered adaptor molecules. However, both genetic capsid modifications and bridging adaptors have to be specifically tailored for each particular targeting situation. Here, we present an efficient and versatile strategy allowing the direct use of monoclonal antibodies against cell surface antigens for targeting of adenovirus vectors. A synthetic 33-amino-acid immunoglobulin G (IgG)-binding domain (Z33) derived from staphylococcal protein A was inserted into the adenovirus fiber protein. The fiber retained the ability to assemble into trimers, bound IgG with high affinity (Kd = 2.4 nM), and was incorporated into vector particles. The transduction efficiency of the Z33-modified adenovirus vector in epidermal growth factor receptor (EGFR)-expressing cells was strongly and dose-dependently enhanced by combination with an EGFR-specific monoclonal antibody. The antibody-mediated increase in cellular transduction was abolished in the presence of competing protein A. In targeting experiments with differentiated primary human muscle cells, up to a 77-fold increase in reporter gene transfer was achieved by preincubation of the vector with monoclonal antibodies directed against neuronal cell adhesion molecule or integrin alpha(7), respectively. The IgG-binding adenovirus vector holds promise for directed gene transfer to a wide variety of cell types by simply changing the target-specific antibody.
Collapse
Affiliation(s)
- Christoph Volpers
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Christian Thirion
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Volker Biermann
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Stefanie Hussmann
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Helmut Kewes
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Patrick Dunant
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Helga von der Mark
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Andreas Herrmann
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| | - Stefan Kochanek
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
- Corresponding author. Mailing address: Center for Molecular Medicine, University of Cologne, Kerpener Str. 34, 50931 Cologne, Germany. Phone: 49 221 4783194. Fax: 49 221 4783510. E-mail:
| | - Hanns Lochmüller
- Center for Molecular Medicine (ZMMK) and Institute for Genetics, University of Cologne, D-50931 Cologne, Gene Center, Friedrich Baur Institute, Department of Neurology, University of Munich, D-81377 Munich, Cardion AG, D-40699 Erkrath, Nikolaus Fiebinger Center for Molecular Medicine, University of Erlangen, D-91054 Erlangen, Germany
| |
Collapse
|